成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> Neuropsychiatric Disease and Treatment >>article
Neuropsychiatric Disease and Treatment

Neuropsychiatric Disease and Treatment

IF: 3.2
Download PDF

Memantine: efficacy and safety in mild-to-severe Alzheimer's disease.

Published:1 April 2007 DOI: 10.2147/nedt.2007.3.2.245 PMID: 19300557
Rajesh R Tampi, Christopher H van Dyck

Abstract

Alzheimer's disease (AD) is the most common cause of dementia, accounting for 25 million cases worldwide. Until recently, the pharmacotherapy of AD was limited to the use of cholinesterase inhibitors (ChEIs) that are approved only for the mild to moderate stages of the illness. Memantine, an NMDA receptor antagonist has been found to be effective, both as monotherapy and in combination with donepezil, in the treatment of patients with moderate to severe stage AD. More recent studies have examined the role of memantine in the treatment of the mild to moderate stages of the disease, although the collective results of these studies remain inconclusive. Available pharmacoeconomic data indicate that treatment with memantine is cost-effective when compared with no treatment in patients with moderate to severe AD. Memantine treatment is predicted to be associated with lower costs of care, longer time to dependence and institutionalization, and gains in quality-adjusted life-years. In this article, we review the evidence for the use of memantine in patients with AD, ranging from the mild to severe stages of disease.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Donepezil 120014-06-4 C24H29NO3 379 suppliers $5.00-$2674.98
Memantine 19982-08-2 C12H21N 202 suppliers $65.00-$1275.12

Similar articles

IF:5.4

Huperzine A and Its Neuroprotective Molecular Signaling in Alzheimer's Disease.

ACS Applied Energy Materials María Jesús Friedli, Nibaldo C Inestrosa,etc Published: 29 October 2021
IF:3.5

Naringenin: A prospective therapeutic agent for Alzheimer's and Parkinson's disease

Journal of Food Biochemistry Ahsas Goyal, Aanchal Verma,etc Published: 15 September 2022
IF:3.9

Magnesium may be an effective therapy for Alzheimer's disease.

World Journal of Psychiatry Dao-Yun Lei, Jie Sun,etc Published: 19 September 2022